Company Overview - Avantor provides products and services for the life sciences, healthcare, and advanced technology industries, supporting complex research, development, and production workflows for clients [5] - The company offers a broad portfolio of laboratory materials, consumables, equipment, and specialty procurement services, generating revenue through high-purity chemicals, reagents, lab supplies, and value-added services [7] Financial Performance - Avantor reported a revenue of $6.55 billion for the trailing twelve months (TTM), reflecting a 3% decline compared to the previous year [8] - The company experienced a net loss of $530.2 million for the full year, a significant drop from a profit of $711.5 million in 2024 [8] - As of the latest data, Avantor's stock price was $7.80, down 50% over the past year, underperforming the S&P 500's approximately 20% gain during the same period [6] Recent Developments - Eversept Partners increased its position in Avantor by acquiring 2,252,202 shares, valued at an estimated $27.72 million, bringing its total holdings to 3,176,644 shares worth $36.40 million [2][6] - The value of Eversept's stake in Avantor rose by $24.87 million, influenced by both trading activity and stock price movement [2] - Avantor's "Revival program," aimed at optimizing its go-to-market strategy, upgrading its e-commerce channel, and relaunching its VWR brand, was highlighted by CEO Emmanuel Ligner as a key initiative for recovery [8][10] Investment Strategy - Eversept's investment in Avantor represents 1.83% of its reported U.S. equity holdings, indicating a diversified strategy focused on the broader life sciences ecosystem, alongside other biotech and healthcare innovators [6][9] - The success of Avantor's "Revival" program is seen as critical for long-term investors, with potential for improved growth and margin stabilization, which could enhance the company's valuation in the future [10]

Summary of Conference Call Company and Industry - **Company**: Waters Corporation - **Industry**: Life Science Tools and Diagnostics Key Points and Arguments Business Overview - The CEO, Udit Batra, emphasized the strength of the acquired BD business, noting its strong brand recognition in flow cytometry and microbiology, with gross margins around 60% [4][5] - The integration of the BD business is ongoing, with a focus on improving execution and precision in operations [5][6] Q4 Performance - BD experienced an 11% decline in Q4, attributed to three non-recurring items and one recurring item, leading to flat growth when adjusted [10][11] - The recurring item, DRG headwinds in China, is expected to persist into the current year, impacting guidance [11][12] Future Guidance - For Q1, a decline of 2.5% is anticipated, with expectations of flat to low single-digit growth in Q2 and Q3, and low to mid-single-digit growth in Q4 [11][12] - The CEO expressed confidence in achieving EPS growth commitments despite current challenges [12] Bioscience Business - The bioscience business was down 10%, underperforming compared to market expectations, which should have been low to mid-single digits [15][16] - The CEO highlighted the need for improved precision in management and execution to address underperformance [23][24] Pricing Strategy - The bioscience business has been passing on only 0-50 basis points of pricing, which is below expectations given its differentiated portfolio [25][26] - The CEO emphasized the importance of focusing on pricing improvements and distribution strategies [25][26] Core Waters Business - The core Waters business is expected to grow organically at 6.25% in 2026, with strong performance in chemistry and service segments [32][36] - New product launches and improved service attachment rates are anticipated to drive growth [38][39] LC-MS Replacement Cycle - The LC-MS replacement cycle is expected to return to high single digits by mid-2027, with ongoing discussions about reshoring contributing to growth [41][46] Margin Expectations - BD's operating margin is projected to normalize around 22.4%, with cost adjustments and tariff implementations expected to contribute positively [72][86] - The CEO noted that pricing improvements are necessary to achieve desired margins, with current pricing at 50 basis points [86] Organizational Focus - The CEO plans to focus on specific business areas, particularly the reagents business, while ensuring accountability and support for teams [92][96] - Cross-pollination of successful strategies among teams is encouraged to enhance overall performance [96] Additional Important Content - The CEO highlighted the importance of precision in forecasting and execution, particularly in response to external challenges such as government shutdowns [14][23] - There is a strong emphasis on the engagement and energy within the organization, with a commitment to improving operational efficiencies and customer relationships [8][90]

Group 1 - Thermo Fisher Scientific Inc. reported fiscal Q4 revenue growth of 7% to $12.21 billion, with GAAP diluted earnings per share increasing by 9% to $5.21 and adjusted EPS rising by 8% to $6.57 [1] - For the full year 2025, revenue grew by 4% to $44.56 billion, with GAAP diluted earnings per share increasing by 7% to $17.74 and adjusted EPS growing by 5% to $22.87 [1] - Following the earnings update, Citi raised the price target for Thermo Fisher to $685 from $660 while maintaining a Buy rating, and Baird increased its price target to $653 from $645, also maintaining an Outperform rating [2] Group 2 - Thermo Fisher Scientific Inc. provides a range of products and services including analytical instruments, reagents, equipment, software, and services for analysis, research, diagnostics, and discovery [3] - The company operates through several segments: Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics [3]

Core Insights - Revvity, Inc. (RVTY) has a market capitalization of $11.4 billion and operates in the global health sciences sector, providing advanced instruments, reagents, software, and services for diagnostics, genomics, drug discovery, and life sciences research [1] Stock Performance - Over the past 52 weeks, RVTY shares have declined by 12.5%, underperforming the S&P 500 Index, which has gained nearly 13%. However, on a year-to-date basis, RVTY shares have increased by 3.7%, outperforming the S&P 500's marginal return [2] - RVTY shares have also lagged behind the State Street Health Care Select Sector SPDR ETF (XLV), which has seen a 6.5% increase over the same period [3] Financial Performance - Revvity reported Q4 2025 results with revenue of $772 million and adjusted EPS of $1.70, driven by strong growth in Diagnostics, which saw fourth-quarter revenue of $390 million, reflecting a 10% reported growth and 7% organic growth. The company has provided optimistic guidance for full-year 2026, forecasting revenue between $2.96 billion and $2.99 billion, with 2% to 3% organic growth and adjusted EPS of $5.35 to $5.45 [6] - For the fiscal year ending December 2026, analysts expect RVTY's adjusted EPS to grow by 6.9% year-over-year to $5.41. The company has a strong earnings surprise history, having exceeded consensus estimates in the last four quarters [7] Analyst Ratings - Among 18 analysts covering RVTY, the consensus rating is a "Moderate Buy," consisting of eight "Strong Buy" ratings, one "Moderate Buy," and nine "Holds" [7] - Baird analyst Catherine Ramsey Schulte raised the price target on Revvity to $129 while maintaining an "Outperform" rating. The mean price target of $119.40 indicates a 19% premium to RVTY's current price levels, while the highest price target of $140 suggests a potential upside of 39.5% [8]

QuidelOrtho Fourth Quarter and Full-Year 2025 Financial Results February 11, 2026 QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 2 Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly his ...

Core Insights - Bio-Techne Corporation reported flat net sales and organic revenue of $295.9 million for the second quarter of FY2026, with a favorable foreign currency impact of 2% and an unfavorable impact from non-recurring prior year revenue of 2% [6][8] - The company achieved a GAAP EPS of $0.24, up from $0.22 in the same quarter last year, and a 15% increase in GAAP operating income to $54.5 million [7][8] - Adjusted EPS rose to $0.46 from $0.42 year-over-year, with adjusted operating income increasing to $92.0 million, reflecting ongoing productivity and cost containment initiatives [8][9] Financial Performance - Revenue for the second quarter was $295.9 million, with reported and organic growth flat compared to the prior year [6][8] - GAAP operating margin improved to 18.4% from 16.0% in the same quarter last year, driven by profitability initiatives and the Exosome Diagnostics divestiture [7][9] - Adjusted operating margin increased to 31.1%, up 100 basis points from the prior year, indicating effective cost management [8][9] Segment Results - The Protein Sciences segment generated net sales of $215.1 million, a 2% increase from $211.6 million in the same quarter last year, although organic revenue decreased by 1% [11] - The Diagnostics and Spatial Biology segment reported net sales of $81.2 million, down 4% from $84.1 million, but organic revenue grew by 3% [12] - The operating margin for the Protein Sciences segment decreased to 39.3% from 41.2%, while the Diagnostics and Spatial Biology segment's operating margin increased to 10.4% from 3.9% [11][12] Company Overview - Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostics, generating over $1.2 billion in net sales in fiscal 2025 [13] - The company has a diverse portfolio that supports high-growth applications in science and medicine, celebrating its 50th anniversary in 2026 [4][13]

Core Viewpoint - Thermo Fisher Scientific Inc. is poised to report strong quarterly earnings, with anticipated growth in both earnings per share and revenue, reflecting its robust market position and demand for its products [1][2]. Financial Performance - Analysts expect Thermo Fisher to report an earnings per share (EPS) of $6.43, representing a 5.4% increase from the same period last year [2][6]. - Projected revenue is approximately $11.94 billion, indicating a 4.8% year-over-year growth [2][6]. Market Reactions - There has been a slight downward revision of 0.1% in the consensus EPS estimate over the past month, which may influence short-term stock price movements [3]. Valuation Metrics - The company has a price-to-earnings (P/E) ratio of approximately 35.90, indicating strong investor confidence in future growth prospects [4][6]. - The price-to-sales (P/S) ratio stands at about 5.36, reflecting the value placed on each dollar of sales [4][6]. - The enterprise value to sales ratio is around 6.13, and the enterprise value to operating cash flow ratio is approximately 35.04, highlighting the company's valuation in relation to its sales and cash flow [5]. Financial Health - Thermo Fisher maintains a debt-to-equity ratio of approximately 0.70, indicating a moderate level of debt compared to its equity [5]. - A current ratio of about 1.50 suggests good liquidity to cover short-term liabilities [5].

Core Viewpoint - Revvity, Inc. is a life sciences and diagnostics company with a market cap of $11.1 billion, providing essential tools for genetic screening and infectious disease testing [1] Financial Performance - Analysts anticipate Revvity to report an adjusted earnings of $1.54 per share for the fourth quarter, reflecting an 8.5% increase from $1.42 per share in the same quarter last year [2] - For fiscal 2025, adjusted EPS is expected to be $4.91, slightly up from $4.90 in 2024, with a projected 8.2% annual increase to $5.31 per share in fiscal 2026 [3] Stock Performance - RVTY stock has decreased by 12.4% over the past 52 weeks, underperforming compared to the Healthcare Select Sector SPDR Fund's 13% increase and the S&P 500 Index's 16.9% gain [4] Growth and Profitability Challenges - Revvity has experienced weak underlying growth with constant-currency revenue growth averaging only 2% over the last two years, indicating soft demand [5] - Profitability has declined, with adjusted operating margin decreasing by over 9 percentage points in the past five years due to rising costs and limited operating leverage [5] - Financial performance has deteriorated, with both revenue and EPS declining annually over the past five years, leading to cautious investor sentiment [5]

Company Overview - Bio-Techne Corporation (TECH) has a market cap of $9.1 billion and operates in the life sciences sector, focusing on reagents, instruments, and services for research, diagnostics, and bioprocessing markets [1] - The company is classified as a "mid-cap" stock, with offerings that support applications in protein analysis, molecular diagnostics, oncology, and genetic research [2] Stock Performance - Shares of Bio-Techne have decreased nearly 26% from their 52-week high of $79.28, while the stock has increased 13.7% over the past three months, lagging behind the Health Care Select Sector SPDR Fund's (XLV) 14% gain [3] - On a year-to-date (YTD) basis, TECH stock is down 18.5%, underperforming XLV's 13.5% rise, and has declined 22.5% over the past 52 weeks compared to XLV's 10.7% return [4] Recent Financial Performance - In Q1 2026, Bio-Techne reported a 1% year-over-year revenue decline to $286.6 million, attributed to a 3% organic decline in Protein Sciences and a 4% decline in Diagnostics and Spatial Biology [5] - The revenue decline was influenced by cell therapy timing headwinds, which reduced growth by 200 basis points in Q1 and are expected to worsen to 400 basis points in Q2, alongside ongoing biotech funding softness [5] Analyst Sentiment - Despite the stock's underperformance, analysts maintain a bullish outlook, with a consensus rating of "Strong Buy" from 15 analysts and a mean price target of $68.58, indicating a potential upside of 16.9% from current levels [6]

Core Thesis - Bio-Techne Corporation is positioned as a global leader in life-science consumables and specialized tools, with a strong focus on research, diagnostics, and emerging therapies [2][3] Company Overview - Founded in 1976, Bio-Techne has undergone strategic pivots and acquisitions, currently led by CEO Kim Kelderman and CFO Jim Hippel [2] - The company operates with a performance-aligned compensation framework and has broad analyst coverage [2] Revenue Generation - Bio-Techne generates most of its revenue from high-quality, premium-priced consumables, holding a 30-40% market share in cytokines and growth factors, approximately 5% in antibodies, and a leadership position in cited proteins [3] - The product portfolio includes reagents, assays, instruments, and proprietary platforms, primarily sold direct-to-consumer with distributor partnerships, notably with Thermo Fisher [3] Market Position and Growth - Despite intense competition, Bio-Techne's premium brand, scale advantages, and diverse applications support its market share growth in precision medicine, biologics, and spatial biology [4] - The company has launched 800 new products in 2024 and expanded its total addressable market (TAM) from $3 billion to approximately $28 billion since 2013 [4] Financial Strength - Bio-Techne maintains solid financial strength with conservative leverage, strong free cash flow, and capacity for further acquisitions [5] - Current valuation reflects compressed multiples and cautious sentiment rather than a decline in fundamentals, indicating a compelling investment opportunity [5] Historical Performance - The stock price has appreciated approximately 34.8% since May 2025, driven by improved demand trends and solid core franchises [6] - The long-term TAM expansion is emphasized as a key factor for continued growth [6]